JP2019513009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513009A5 JP2019513009A5 JP2018545230A JP2018545230A JP2019513009A5 JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5 JP 2018545230 A JP2018545230 A JP 2018545230A JP 2018545230 A JP2018545230 A JP 2018545230A JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune cell
- modified immune
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims 1
- 101150064015 FAS gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088103A JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/US2017/019301 WO2017147383A1 (en) | 2016-02-25 | 2017-02-24 | Modified cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Division JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513009A JP2019513009A (ja) | 2019-05-23 |
| JP2019513009A5 true JP2019513009A5 (cg-RX-API-DMAC7.html) | 2020-04-02 |
| JP7082574B2 JP7082574B2 (ja) | 2022-06-08 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2018545230A Active JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11434294B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3420000A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7080819B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190003938A (cg-RX-API-DMAC7.html) |
| CN (3) | CN116082505A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017223846A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112018067696A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3014067A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2903408T3 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2018128462A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201807188VA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2017144681A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| EP3420000A1 (en) * | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| DK3551221T3 (da) | 2016-12-08 | 2022-01-24 | Immatics Biotechnologies Gmbh | Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf |
| EA201991431A1 (ru) | 2016-12-16 | 2020-01-17 | Б-Моген Биотехнолоджис, Инк. | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| IL268479B2 (en) | 2017-02-21 | 2024-06-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| AU2018251898A1 (en) | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| KR20250010750A (ko) * | 2017-12-20 | 2025-01-21 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| KR102795692B1 (ko) | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| JP2021515806A (ja) | 2018-03-02 | 2021-06-24 | シーディアール−ライフ・アクチェンゲゼルシャフトＣｄｒ−Ｌｉｆｅ Ａｇ | 三重特異性抗原結合タンパク質 |
| CA3095076A1 (en) * | 2018-03-29 | 2019-10-03 | Adagene Inc. | Anti-pd-l1 antibodies and use thereof |
| JP7518771B2 (ja) * | 2018-06-04 | 2024-07-18 | ディアテーバ ソチエタ レスポンサビリタ リミタータ | 抗ｃｄ９９ダイアボディ又はｉｇｇ抗体及びそれらの使用 |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102250234B1 (ko) * | 2018-06-29 | 2021-05-10 | 주식회사 와이바이오로직스 | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 |
| JP7617839B2 (ja) | 2018-07-09 | 2025-01-20 | プレシゲン，インコーポレイテッド | 融合構築物およびその使用法 |
| AU2019354395A1 (en) * | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| JP2022512766A (ja) * | 2018-10-17 | 2022-02-07 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| KR20210112310A (ko) * | 2018-12-06 | 2021-09-14 | 광동 티씨알큐어 바이오파마 테크놀로지 씨오., 엘티디. | 종양 항원, tgf-베타 및 면역체크포인트를 표적으로 하는 tcr-t 세포 복합 치료법 |
| US20220144960A1 (en) | 2018-12-26 | 2022-05-12 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| MX2021009020A (es) * | 2019-01-28 | 2021-09-28 | Xyphos Biosciences Inc | Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car. |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CA3134465A1 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| MX2021015670A (es) * | 2019-07-02 | 2022-04-18 | Telix Int Pty Ltd | Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal. |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| CN114901677A (zh) * | 2019-11-04 | 2022-08-12 | 艾诺奥医药品有限公司 | 治疗脑癌的联合疗法 |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| JP2023515747A (ja) * | 2019-12-28 | 2023-04-14 | シャンハイ セル セラピー グループ カンパニー カンパニー リミテッド | 免疫調節分子を発現する細胞および免疫調節分子を発現するための系 |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| JP2023519926A (ja) * | 2020-03-23 | 2023-05-15 | キュリジン カンパニー，リミテッド | 二重特異性核酸分子を含む抗癌ウイルスの構造 |
| CN116829597A (zh) * | 2020-05-14 | 2023-09-29 | 维尔托索宾科公司 | 人源化cd38和icam1抗体及其用途 |
| CN116209749A (zh) * | 2020-06-11 | 2023-06-02 | 创新细胞治疗控股有限公司 | 靶向mage-a4肽的细胞/基因疗法 |
| US20230227557A1 (en) * | 2020-06-25 | 2023-07-20 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| AU2021305234A1 (en) | 2020-07-10 | 2023-02-09 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| IL302568A (en) * | 2020-11-04 | 2023-07-01 | Senti Biosciences Inc | Protein payload release |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| EP4251190A4 (en) * | 2020-11-30 | 2024-10-23 | Fred Hutchinson Cancer Center | PD-L1-BINDING PEPTIDES, PEPTIDE COMPLEXES AND METHODS OF USE THEREOF |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| CN118019842A (zh) * | 2021-07-01 | 2024-05-10 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| CA3228663A1 (en) | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals, Inc | Combination therapy to treat brain cancer |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| KR20240135662A (ko) * | 2022-01-28 | 2024-09-11 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 자연 살해 t-세포 및 이의 사용 방법 |
| CN118005806A (zh) * | 2024-02-08 | 2024-05-10 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1445264B1 (en) | 2001-07-31 | 2011-09-14 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
| US8853362B2 (en) | 2002-05-22 | 2014-10-07 | Esbatech, An Alcon Biomedical Research Unit Llc | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| KR101573086B1 (ko) | 2007-06-25 | 2015-11-30 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체 |
| RU2514658C2 (ru) | 2008-06-25 | 2014-04-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | Оптимизация растворимости иммуносвязывающих средств |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| WO2013040371A2 (en) | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| IL313351A (en) | 2013-06-26 | 2024-08-01 | Numab Therapeutics AG | New frameworks for antibodies |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| AU2015269219B2 (en) * | 2014-06-06 | 2020-12-24 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| DK3189073T4 (da) | 2014-09-04 | 2025-08-18 | Cellectis | Trofoblastglykoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi |
| EP3198010B1 (en) | 2014-09-26 | 2020-11-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| CA2965521A1 (en) | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| IL252295B2 (en) | 2014-12-19 | 2023-10-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of using them |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP3420000A1 (en) | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
-
2017
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja active Active
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja active Active
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned